PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

@article{Gopal2014PI3KIB,
  title={PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.},
  author={Ajay K Gopal and Brad S Kahl and Sven de Vos and Nina D. Wagner-Johnston and Stephen J. Schuster and Wojciech Jurczak and Ian W Flinn and Christopher R Flowers and Peter Martin and Andreas a Viardot and Kristie A Blum and Andre H. Goy and Andrew J. Davies and Pier Luigi Zinzani and Martin Dreyling and Dave Johnson and Langdon L. Miller and Leanne Holes and Daniel Li and Roger Delemere Dansey and Wayne R. Godfrey and Gilles A Salles},
  journal={The New England journal of medicine},
  year={2014},
  volume={370 11},
  pages={
          1008-18
        }
}
BACKGROUND Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals that promote the growth and survival of malignant B lymphocytes. In a phase 1 study, idelalisib, an orally active selective PI3Kδ inhibitor, showed antitumor activity in patients with previously treated indolent non-Hodgkin's lymphomas. METHODS In this single-group, open-label, phase 2 study, 125 patients with indolent non-Hodgkin's lymphomas who had not had a… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 256 CITATIONS

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 17 Highly Influenced Citations

  • Averaged 53 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 29 REFERENCES

Similar Papers

Loading similar papers…